Hormone replacement therapy, thrombosis and thrombophilia

Area of Science:

• Endocrinology
• Hematology
• Reproductive Medicine

Background:

• Hormone replacement therapy (HRT) is associated with an increased risk of venous thromboembolism (VTE).
• Individuals with a personal or family history of thrombosis or hereditary thrombophilia have a pre-existing elevated VTE risk.
• The interplay between HRT and inherited thrombotic predisposition requires careful consideration.

Purpose of the Study:

• To estimate the absolute risk of VTE associated with HRT in specific patient groups.
• To provide practical guidance on HRT use for individuals with increased thrombotic risk.
• To evaluate the role and utility of thrombophilia screening in this context.

Main Methods:

• Review and synthesis of existing epidemiological data on HRT and VTE.
• Risk assessment modeling for different demographic and clinical subgroups.
• Analysis of guidelines and expert opinions on thrombophilia testing.

Main Results:

• HRT significantly increases the absolute risk of VTE, with varying magnitudes depending on individual risk factors.
• The combined risk of HRT and pre-existing thrombotic conditions is substantially higher than with HRT alone.
• Thrombophilia screening may identify individuals at disproportionately higher risk, informing HRT decisions.

Conclusions:

• HRT should be prescribed cautiously in women with a history of thrombosis or hereditary thrombophilia.
• Personalized risk-benefit assessment is crucial before initiating HRT in high-risk individuals.
• The role of routine thrombophilia screening prior to HRT warrants further investigation and clinical validation.